| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -7.9 | -15.8 |
| EPS (diluted, $ a share) | $-4.74 | $-13.43 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, OTC: BCAB. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
BioAtla, Inc.: key numbers
- Share price
- $1.99Close, Nov 16
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from BioAtla, Inc.
All →BioAtla Capital Raise
BioAtla, Inc. entered into a Standby Equity Purchase Agreement (SEPA) with Yorkville, establishing a facility to sell up to $40.0 million of common stock at the company's option. Shares will be sold at 97% of the lowest daily VWAP over a three-day pricing period following an advance notice. As consideration, the company agreed to pay a $500,000 commitment fee, partially settled through the issuance of warrants for 182,110 shares.
- Counterparty
- YA II PN, Ltd.
- Term
- 36 months
BioAtla Leadership Change
Dr. Eric Sievers resigned as Chief Medical Officer of BioAtla, Inc. effective September 25, 2026, and will transition to a consulting role through June 2027. Additionally, the company reinstated retention bonus programs for CEO Jay M. Short and CFO Christian Vasquez, contingent on achieving financial and capital raising milestones by year-end 2026.